Skip Navigation


Annals of Oncology Advance Access originally published online on May 13, 2005
Annals of Oncology 2005 16(8):1219-1221; doi:10.1093/annonc/mdi255
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
16/8/1219    most recent
mdi255v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Colleoni, M.
Right arrow Articles by Goldhirsch, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colleoni, M.
Right arrow Articles by Goldhirsch, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Editorial

Treatment of advanced breast cancer: the good, the bad and the ugly

M. Colleoni1,*, S. Gelber2,3 and A. Goldhirsch1

1 Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy2 Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA3 Statistical Center, International Breast Cancer Study Group, Boston, MA, USA

* Email: marco.colleoni@ieo.it

The first 10% of the full text of this article appears below.

Every year more than 1 million women are newly diagnosed with breast cancer, and this figure will likely reach 1.5 million with the increased number of cases arising in developing countries [1Go]. Many of these patients will be offered adjuvant treatment based on consideration of disease responsiveness to specific therapies [2Go], and almost half eventually will have local or distant relapses.

 Metastatic, or advanced, breast cancer is a chronic disease requiring specific strategies to control disease progression and related symptoms. The treatment choice is often based on evidence obtained from trials designed to investigate therapy-related issues such as whether one treatment yields better responses or longer time to progression. These trials frequently evaluate whether a given treatment is effective in a selected group of patients, usually using measurable or evaluable disease to guide patient selection and avoiding, for example, those with only . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
D. Tassinari, B. Poggi, M. Fantini, E. Tamburini, S. Nicoletti, and S. Sartori
Cost-opportunity analysis in clinical oncology: from the 'wild far-west' to a correct integration of the disciplines, avoiding the 'war of the worlds'
Ann. Onc., May 1, 2006; 17(5): 876 - 877.
[Full Text] [PDF]